HippoScreen Neurotech (宏智生醫科技)

HippoScreen operates at the intersection of mental healthcare, EEG hardware, and software-based clinical assessment. Its SEA System aims to add an objective brainwave signal to depression assessment, which is commonly based on clinicians’ evaluation of reported symptoms. The company describes a compact workflow—eight EEG channels and approximately two minutes from measurement to assessment report—and reports above 80% accuracy in clinical-data evaluation. These features distinguish its stated approach from symptom-only screening, but do not establish clinical adoption, regulatory status, or comparative superiority. It is therefore not possible to make a grounded competitor ranking or market-share comparison. The company also describes development of EEG algorithms for ADHD, Alzheimer’s disease, and mild cognitive impairment, suggesting ambitions beyond depression assessment. Its $3.9 million across two rounds, including a $2.5 million corporate round in 2021, indicates early-stage financing history rather than evidence of scaled commercial reach.

HippoScreen was founded in 2019 and raised $1.4 million in an angel round dated Mar 1, 2019, followed by a $2.5 million corporate round on Feb 8, 2021. Compal Electronics is listed as the investor in both rounds, bringing recorded total funding to $3.9 million. The initial product direction centers on the SEA System, an EEG-based assessment system for mental-health conditions, with the company describing a two-minute assessment workflow and eight-channel data capture. CES-related coverage in 2020 and a 2019 report on its AI-based brainwave diagnostic system mark early visibility for the product concept. A brainwave monitoring patent publication followed on Mar 10, 2021, although no granted patents are listed. The company has also described algorithm development for ADHD, Alzheimer’s disease, and mild cognitive impairment, which could broaden its clinical scope if those products progress. The financing and product-development record therefore shows early technical and funding milestones, while the pace and scale of later growth remain unclear.